HIGHLIGHTS
- who: Sara Fancelli from the University of Pisa, Italy have published the paper: KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population, in the Journal: (JOURNAL)
- what: The authors investigate the prognostic role of KRAS G12 mutations according to patients and disease characteristics and treatment chosen. Despite the limitations derived from the retrospective characteristics of the study and the relative lack of comutation assessment, the authors can affirm that, to the knowledge , this is the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.